7Baggers
 Enanta Pharmaceuticals raises $74.75 million in public offering By Investing.com  Investing.com Canada Thu, 02 Oct 2025 21:03:32 GMT
 Enanta Pharmaceuticals Announces Public Stock Offering  TipRanks Wed, 01 Oct 2025 21:09:48 GMT
 Jefferies Upgrades Enanta Pharma (ENTA) Rating to 'Buy' with Rai  GuruFocus Wed, 01 Oct 2025 17:18:43 GMT
 Enanta Pharmaceuticals launches $50 million public stock offering By Investing.com  Investing.com Nigeria Wed, 01 Oct 2025 06:35:58 GMT
 enanta pharma slides after $50 mln stock offering unveiled  TradingView Tue, 30 Sep 2025 20:59:45 GMT
 Enanta Pharmaceuticals launches $50 million public stock offering  Investing.com India Tue, 30 Sep 2025 20:52:02 GMT
 Enanta up 92% as zelicapavir’s RSV journey goes on  The Pharma Letter Tue, 30 Sep 2025 13:28:00 GMT
 Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Raised to $28.00  MarketBeat Tue, 30 Sep 2025 12:20:05 GMT
 Enanta Pharmaceuticals stock holds Buy rating at H.C. Wainwright  Investing.com Tue, 30 Sep 2025 11:43:00 GMT
 Enanta stock doubles despite RSV trial missing primary endpoint  Clinical Trials Arena Tue, 30 Sep 2025 10:52:30 GMT
 enanta pharmaceuticals stock price target raised to $9 by leerink on rsv data  Investing.com Canada Tue, 30 Sep 2025 09:44:00 GMT
 enanta’s rsv treatment misses main goal in mid-stage study  whbl.com Tue, 30 Sep 2025 00:52:07 GMT
 Enanta Plans Phase III Trial Of Zelicapavir Despite Primary Endpoint Miss  insights.citeline.com Mon, 29 Sep 2025 20:30:05 GMT
 Enanta Pharmaceuticals (ENTA) Stock Surges Despite Trial Setback  GuruFocus Mon, 29 Sep 2025 15:14:24 GMT
 Enanta presses ahead with RSV drug despite primary endpoint miss  FirstWord Pharma Mon, 29 Sep 2025 15:13:26 GMT
 Enanta’s stock nearly doubles on strong RSV data  BioWorld MedTech Mon, 29 Sep 2025 15:00:00 GMT
 Enanta shares rise despite RSV trial failing to meet main goal  Seeking Alpha Mon, 29 Sep 2025 14:33:53 GMT
 Enanta weakens on RSV treatment trial readout  pharmaphorum Mon, 29 Sep 2025 12:18:57 GMT
 enanta (enta) unveils promising phase 2b study results for zelic  GuruFocus Mon, 29 Sep 2025 11:22:52 GMT
 Enanta stock tumbles after RSV drug misses primary endpoint  Investing.com Mon, 29 Sep 2025 11:03:45 GMT
 enanta's rsv treatment misses main goal in mid-stage study  TradingView Mon, 29 Sep 2025 10:49:54 GMT
 Enanta Pharmaceuticals (ENTA) Rises on Anticipated RSV Trial Dat  GuruFocus Mon, 29 Sep 2025 09:59:59 GMT
 enanta pharmaceuticals (enta) to reveal key rsv trial data  GuruFocus Sat, 27 Sep 2025 18:02:23 GMT
 Enanta to post mid-stage trial data for RSV drug (ENTA:NASDAQ)  Seeking Alpha Sat, 27 Sep 2025 13:08:56 GMT
 4 analysts have this to say about enanta pharma  Benzinga Mon, 15 Sep 2025 07:00:00 GMT
 nuveen llc invests $313,000 in enanta pharmaceuticals, inc. $enta  MarketBeat Fri, 12 Sep 2025 03:29:36 GMT
 nuveen llc invests $313,000 in enanta pharmaceuticals, inc. $enta  MarketBeat Thu, 11 Sep 2025 09:40:49 GMT
 enanta at baird conference: optimism in virology and immunology  Investing.com India Thu, 11 Sep 2025 00:09:04 GMT
 enanta at baird conference: optimism in virology and immunology  Investing.com Wed, 10 Sep 2025 22:58:02 GMT
 published on: 2025-09-03 22:40:38  Newser Thu, 04 Sep 2025 03:40:38 GMT
 enanta pharmaceuticals chief financial, administrative officer dies  MarketScreener Wed, 03 Sep 2025 10:35:36 GMT
 published on: 2025-09-03 03:49:04  Newser Wed, 03 Sep 2025 08:49:04 GMT
 enanta pharmaceuticals announces passing of longtime cfo paul mellett  Investing.com Wed, 03 Sep 2025 07:00:00 GMT
 enanta cfo dies after taking medical leave of absence  CFO Dive Wed, 03 Sep 2025 07:00:00 GMT
 enanta pharma (enta) receives new 'buy' rating from westpark cap  GuruFocus Tue, 02 Sep 2025 12:17:42 GMT
 paul j. mellett, jr. obituary august 31, 2025  James H. Delaney and Son Funeral Home Sun, 31 Aug 2025 07:00:00 GMT

Enanta Pharmaceuticals, Inc
(NASDAQ:ENTA) 

ENTA stock logo

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovi...

Founded: 1995
Full Time Employees: 141
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends